Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has
initiated the first phase of branding its lead drug candidate, Oncoprex(TM)
immunogene therapy, and has completed and submitted non-proprietary drug name
selections to the American Medical Association’s United States Adopted Names
(“USAN”) Council. According to the update, Genprex will, upon receipt of USAN
feedback expected later this year, submit its non-proprietary drug name
selections to the World Health Organization for International Nonproprietary
Names (“INN”) status. By mid-2020, the company expects to obtain an approved
non-proprietary drug name. “Developing and obtaining regulatory approval of a
non-proprietary drug name is a requirement for bringing our lead drug candidate
to market,” Genprex Chairman and CEO Rodney Varner said in the news release. “We’re
one step closer to achieving this regulatory milestone. An approved
non-proprietary drug name will also make our lead drug candidate more widely
recognizable to clinicians and physicians and most importantly, to patients
living with non-small cell lung cancer.”
To view the full press release, visit http://ibn.fm/8p8qJ
About Genprex Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer fighting genes by encapsulating them into nanoscale hollow spheres
called nanovesicles, which are then administered intravenously and taken up by
tumor cells where they express proteins that are missing or found in low
quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells, and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment